AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
roughly $1 billion into an end-to-end antibody discovery, development and manufacturing platform and is now advancing internally selected targets. ABCL635 , an NK3R-targeting antibody for menopausal hot flashes, is the lead internal program with a Phase II readout expected in Q3 ("probably sometime after Labor Day"); early Phase I data show clean safety, PK alignment and biomarker target engagement, and the company plans a 80-patient, triple-blinded 2:1 randomized Phase II with plans to expand into cancer therapy–associated VMS and pursue a monthly auto-injector dosing profile. AbCellera completed a new GMP facility and holds about $700 million in cash equivalents and committed funding with an annual run rate near $120 million, positioning the company to push toward roughly five clinical programs and a broader discovery pipeline while remaining flexible on partnering. Interested in AbCellera Biologics Inc.? Here are five stocks we like better. Argenx's 28% Surge & Promising Pr
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- AbCellera Reports Full Year 2025 Business ResultsBusiness Wire
ABCL
Earnings
- 2/24/26 - Beat
ABCL
Sec Filings
- 3/2/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- ABCL's page on the SEC website